Article
A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs.
The Journal of clinical endocrinology and metabolism - 1 May 2010
Durán-Prado Mario, Saveanu Alexandru, Luque Raul M, Gahete Manuel D, Gracia-Navarro Francisco, Jaquet Philippe, Dufour Henry, Malagón María M, Culler Michael D, Barlier Anne, Castaño Justo P
Abstract excerpt
CONTEXT: Somatostatin (SST) receptors, specially sst2 and sst5, provide a valuable target to inhibit excessive hormone release and cell growth in pituitary tumors by using SST analogs (SSAs). Unfortunately, an appreciable proportion of tumors fail to respond to SSA despite expressing high levels of one or more ssts. Recently we identified two novel truncated sst5 variants, sst5TMD5, and sst5TMD4, absent in normal...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.